Symptoms, Possible Manifestations, and Warning Signs of FH-III
At a Glance
Familial hyperaldosteronism type III can cause severe high blood pressure and low potassium, sometimes without noticeable symptoms. Regular blood pressure and laboratory checks are essential, and sudden weakness, stroke signs, chest symptoms, fainting, or paralysis require emergency care.
The symptoms of FH-III can be invisible to others, making it a challenging condition to navigate. The high levels of aldosterone in Familial Hyperaldosteronism Type III (FH-III) create a constant internal struggle for the body. Because the adrenal glands are “stuck” in the on position, they continuously pump out hormones that force the kidneys to hold onto salt and flush out potassium [1][2]. This imbalance leads to possible manifestations that often begin in early childhood. (Note: Because FH-III is rare, there is no universally predictable progression, and severity varies widely).
Everyday Symptoms and Possible Manifestations
In FH-III, symptoms are driven by two main factors: extreme high blood pressure (hypertension) and very low potassium (hypokalemia). FH-III can appear as early as age 2 or 6 [3][4], though milder variants may not follow this severe childhood pattern.
Signs of Low Potassium (Hypokalemia)
More than 85% of people with FH-III experience significant hypokalemia [3]. This is not just a laboratory finding; it affects how muscles and nerves function. Common daily signs include:
- Muscle Issues: Persistent fatigue, muscle cramps, or a feeling of “heavy” limbs [5].
- Kidney Effects: A frequent need to urinate (polyuria), especially at night, and extreme thirst (polydipsia) [3].
- Digestive Changes: Slowed digestion can lead to frequent constipation.
Signs of Extreme Hypertension
Because the blood pressure in FH-III is often resistant to standard medications, it can reach very high levels early in life [2][3]. You or your child may experience:
- Frequent, severe headaches.
- Unexplained nosebleeds.
- A “pounding” sensation in the chest or ears.
- Exercise intolerance (getting tired or out of breath much faster than peers).
Important: These symptoms are nonspecific and should not be used to judge whether blood pressure is controlled. Serious hypertension and hypokalemia can be clinically silent, emphasizing the need for regular measurement and laboratory follow-up even when you feel completely well.
How Genetic Variants Change the Story
Not all cases of FH-III look the same. The severity of symptoms often depends on the specific change (variant) in the KCNJ5 gene.
- Severe Childhood Variants: Some mutations, such as T158A, are known to cause a complete loss of the “filter” in the adrenal cells [6][7]. This leads to massive aldosterone production, severe low potassium, and enlarged adrenal glands (hyperplasia) very early in life [1]. These cases often require surgical removal of the adrenal glands to protect the heart and kidneys [3].
- Milder or Adult-Onset Variants: Other mutations, like Asn179Ser, may present more mildly [8]. Some families with this variant have recurrent low potassium but blood pressure that remains near normal or is easily controlled with medication [8].
- Mosaicism: In rare cases, the mutation is only present in some of the body’s cells rather than all of them. This “mosaic” pattern can result in a much milder course of the disease that is easier to manage with medication alone [9].
When to Seek Emergency Care
While many symptoms of FH-III can be managed at home with your medical team, certain “red flags” indicate a life-threatening situation. High aldosterone levels significantly increase the risk of heart rhythm problems and strokes, even in young children and teenagers [10][11].
Red Flags: Seek Immediate Emergency Care
If any of the following occur, go to the nearest emergency room immediately:
- Neurological Warning Signs: Sudden weakness or numbness (especially on one side of the body), difficulty speaking, drooping in the face, sudden vision loss, or a “worst headache of life” (potential signs of stroke) [11][12].
- Severe Muscle Failure: Sudden inability to move the legs or arms (flaccid paralysis). Seek emergency care immediately regardless of whether a home potassium value is above or below a specific number like 2.5 mmol/L [5].
- Cardiac Distress: Chest pain, a sensation of the heart “skipping beats” or racing wildly (arrhythmia), or unexplained fainting [13].
- Hypertensive Crisis:
- For Adults: Blood pressure readings persistently at or above 180/120 mmHg, especially if accompanied by confusion, seizure, or shortness of breath [14][5].
- For Children: The adult 180/120 threshold is unsafe for a child. Pediatric urgent thresholds depend on the child’s age, sex, and height. Families must obtain an individualized pediatric emergency threshold from their treating team and act upon it.
Over time, untreated FH-III can lead to permanent damage to the heart and kidneys [9][15]. Early recognition of these warning signs and strict adherence to a specialist’s treatment plan—using proper home blood pressure technique—are the best ways to reduce these long-term risks.
Common questions in this guide
What are the most common symptoms of familial hyperaldosteronism type III?
Can FH-III be serious even if I feel well?
How does a KCNJ5 variant affect FH-III symptoms?
When should someone with FH-III go to the emergency room?
What blood pressure reading is an emergency in FH-III?
What can low potassium feel like in FH-III?
Get notified when new evidence is published on Familial hyperaldosteronism type III.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Familial hyperaldosteronism type III.
Monticone S, Tetti M, Burrello J, et al.
Journal of human hypertension 2017; (31(12)):776-781 doi:10.1038/jhh.2017.34.
PMID: 28447626 - 2
SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.
Zennaro MC, Jeunemaitre X
Annales d'endocrinologie 2016; (77(3)):214-9.
PMID: 27315758 - 3
Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism.
Araujo-Castro M, Parra P, Martín Rojas-Marcos P, et al.
Frontiers in endocrinology 2024; (15()):1336306 doi:10.3389/fendo.2024.1336306.
PMID: 38495792 - 4
Familial Hyperaldosteronism Type 3 with a Rapidly Growing Adrenal Tumor: An In Situ Aldosterone Imaging Study.
Takizawa N, Tanaka S, Nishimoto K, et al.
Current issues in molecular biology 2021; (44(1)):128-138 doi:10.3390/cimb44010010.
PMID: 35723389 - 5
Hypertensive Crisis with Neurological Impairment Mimicking a Guillain-Barrè Syndrome: Searching for a Link.
Mazza A, Lucchetta M, Torin G, et al.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2018; (25(4)):421-424 doi:10.1007/s40292-018-0283-y.
PMID: 30298226 - 6
Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma.
Scholl UI, Abriola L, Zhang C, et al.
The Journal of clinical investigation 2017; (127(7)):2739-2750.
PMID: 28604387 - 7
Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production.
Hattangady NG, Karashima S, Yuan L, et al.
Journal of molecular endocrinology 2016; (57(1)):1-11 doi:10.1530/JME-15-0324.
PMID: 27099398 - 8
A NOVEL KCNJ5 GENE MUTATION ASSOCIATED WITH FAMILIAL ALDOSTERONISM TYPE III WITHOUT HYPERTENSION.
Zhou MY, Yu SQ, Zhu SJ, et al.
Georgian medical news 2026; 259-265.
PMID: 42830061 - 9
Mosaicism for KCNJ5 Causing Early-Onset Primary Aldosteronism due to Bilateral Adrenocortical Hyperplasia.
Maria AG, Suzuki M, Berthon A, et al.
American journal of hypertension 2020; (33(2)):124-130 doi:10.1093/ajh/hpz172.
PMID: 31637427 - 10
Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.
Monticone S, D'Ascenzo F, Moretti C, et al.
The lancet. Diabetes & endocrinology 2018; (6(1)):41-50 doi:10.1016/S2213-8587(17)30319-4.
PMID: 29129575 - 11
Primary aldosteronism in young adults with acute stroke: Prevalence and clinical characteristics.
Tang Z, Chen H, He W, et al.
Journal of the neurological sciences 2020; (413()):116774 doi:10.1016/j.jns.2020.116774.
PMID: 32217377 - 12
Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.
Tan ST, Boyle V, Elston MS
Hypertension (Dallas, Tex. : 1979) 2023; (80(7)):1517-1525 doi:10.1161/HYPERTENSIONAHA.123.21054.
PMID: 37170822 - 13
Who should be screened for primary aldosteronism? A comprehensive review of current evidence.
Huang WC, Lin YH, Wu VC, et al.
Journal of clinical hypertension (Greenwich, Conn.) 2022; (24(9)):1194-1203 doi:10.1111/jch.14558.
PMID: 36196469 - 14
SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?
Baguet JP, Steichen O, Mounier-Véhier C, Gosse P
Annales d'endocrinologie 2016; (77(3)):187-91.
PMID: 27087531 - 15
Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism.
Chang YH, Chung SD, Wu CH, et al.
Surgery 2020; (167(2)):367-377 doi:10.1016/j.surg.2019.08.017.
PMID: 31676114
This page is for informational purposes only and does not constitute medical advice. Because emergency thresholds and treatment needs vary, contact your endocrinology team for personalized guidance about blood pressure, potassium, and warning signs.